Which factors limit the use of bone marrow transplantation (BMT) for the treatment of myelodysplastic syndrome (MDS)?

Updated: Jul 24, 2018
  • Author: Emmanuel C Besa, MD; Chief Editor: Koyamangalath Krishnan, MD, FRCP, FACP  more...
  • Print

Because most patients with MDS are elderly and only a few young patients will have a matched donor, the use of bone marrow transplantation is limited. However, in our institution, with a haploidentical (half-match) donor, 2-step protocol, we have shown that expanding the donor pool to include patients' children as well as siblings increases the availability of donors for elderly patients and produces the same result as transplantation from full-match donors. Sandhu et al reported that umbilical cord blood transplantation after reduced-intensity conditioning regimens in patients aged ≥70 years with MDS and AML produced results comparable to those of HLA full-matched sibling donor transplantation in this age group. [35]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!